Merck sold $952 million of its COVID-19 antiviral pill, molnupiravir, in the fourth quarter of 2021 and this year expects to sell an additional $5 billion to $6 billion worth, CNBC reported Feb. 3.
Read the full post on Becker's Hospital Review - Healthcare News
